Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T22:13:08.817Z.
Calculation as of: 2026-10-06T22:13:08.817Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 93909054c420831b7a71ade485d1565ba09f3c5b60377b98c71c30749e6fc511
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
PRF Technologies Ltd.
Market Cap
$70884.00
EV/EBITDA Ratio
N/A
Market Cap
$29771.00
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| PRF Technologies Ltd. (PRFX) | $70884.00 | N/A |
| Akanda Corp. (AKAN)vs › | $61172.00 | N/A |
| Psyence Biomedical Ltd. (PBM)vs › | $95475.00 | N/A |
| Silexion Therapeutics Ltd. (SLXN)vs › | $110112.00 | N/A |
| Zhongchao Inc. (ZCMD)vs › | $30389.00 | N/A |
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR)vs › | $29771.00 | N/A |
| NewGenIvf Group Limited (NIVF)vs › | $6235.00 | N/A |
| SciSparc Ltd. (SPRC)vs › | $250443.00 | N/A |
| Virax Biolabs Group Limited (VRAX)vs › | $378849.00 | N/A |
| Niki BioSolutions, Inc. (NIKI)vs › | $403887.00 | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
